US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Katalysen Ventures announces roadshow starting May 2

Katalysen Ventures AB (publ) (“Katalysen”, the “Company”) is thrilled to announce a roadshow, with stops in Stockholm (May 2, May 22), Geneva (May 14), and Vienna (date tbd). The May 22 stop in Stockholm will be co-hosted with Quantic Financial Solutions (part of C-Quadrat Investment Group), a developer of high end risk & asset management solutions for financial institutions. Katalysen extends a warm welcome to everybody actively engaged in or curious about the European innovation scene for a chance to learn more about Katalysen, its recently announced Venture Targeter Framework, and to

Report for the Second Quarter 2022 in Katalysen Ventures

Summary of report below. Full report attached and available under Investor Relations on Katalysen.com. All currencies in SEK unless otherwise specified.A. VENTURE DEVELOPMENT KPIs (LAST PERIOD WITHIN BRACKETS): · New client agreements during the period: 3 (4) · Active clients at the end of the period: 13 (11) · Total calculated market value of Katalysen’s portfolio (shares, options, and convertibles) at the end of the period: 209.2 MSEK (195 MSEK) · Quarterly portfolio growth (shares and options) excluding new cash invested during the period: 0.4% (5.6%) · Value added to

Katalysen Ventures AB (publ) announces oversubscribed listing issue

On April 10, 2022, the subscription period in Katalysen Ventures AB's (publ) ("Katalysen" or "the Company") new share issue prior to listing on Spotlight Stock Market (the "Listing Issue") ended. A total of approximately SEK 12.5 million was subscribed for in the Listing Issue, corresponding to a subscription ratio of approximately 113 percent. The company will thus receive approximately 130 new shareholders and approximately SEK 11 million before issue costs. Settlement notes are scheduled to be sent today, April 12, 2022. The first day of trading in Katalysen's share on Spotlight Stock

ANNOUNCING PARTNERSHIP AS VENTURE DEVELOPER TO MED4CAST TO PROMOTE THE USE OF AI IN MEDICAL DIAGNOSTICS

Katalysen Ventures is pleased to announce that we have formed a partnership as a venture developer to Swiss digital medtech startup Med4Cast. As a venture developer, Katalysen Ventures has been invited to participate as a co-founder and to invest approximately €12’000 (CHF12’500) at par value. This investment has now been completed, and Katalysen Ventures now owns 20% of Med4cast as a result.Katalysen has been working for more than a year with leading medical, imaging and artificial intelligence experts on developing technology for advanced, machine based, diagnostics in orthopaedics. Given

The subscription period in Katalysen Ventures AB (publ) share issue starts today

Today, 25 March 2022, is the first day of the subscription period in Katalysen Ventures AB (publ)’s (”Katalysen” or the “Company”) share issue prior to planned listing on Spotlight Stock Market (the “IPO”). The subscription period lasts until 10 April 2022. A fully subscribed share issue will provide the Company with a total approx. SEK 11 million before deduction of transaction related costs. Memorandum, teaser and subscription forms are available on the websites of the Company (www.katalysen.com), Nordic Issuing (www.nordic-issuing.se) and Spotlight Stock Market (www.spotlightstockmarket.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media